Compare VYGR & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | UIS |
|---|---|---|
| Founded | 2013 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.6M | 220.2M |
| IPO Year | 2015 | 1994 |
| Metric | VYGR | UIS |
|---|---|---|
| Price | $3.48 | $3.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $5.67 |
| AVG Volume (30 Days) | 568.1K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,135,000.00 | ★ $1,950,100,000.00 |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | $2.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.83 | $1.97 |
| 52 Week High | $5.55 | $4.98 |
| Indicator | VYGR | UIS |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 56.90 |
| Support Level | $3.31 | $3.51 |
| Resistance Level | $4.29 | $4.06 |
| Average True Range (ATR) | 0.20 | 0.38 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 30.77 | 46.02 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.